Truist resumed coverage on Viking Therapeutics with a new price target
Stocks in this Quantisnow insightHealth Care
Historical context for VKTX
Across the 22 sessions after earlier VKTX headlines, the stock closed higher 12 times and lower 10 times, with a median move of 2.3% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | VKTX | SPY |
|---|---|---|---|
| May 21, 2026 | Viking Therapeutics to Participate at Upcoming Investor Conferences | +4.2% | +0.2% |
| May 12, 2026 | Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026 | -1.3% | -0.2% |
| May 5, 2026 | Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026 | -1.4% | +0.8% |
| Apr 30, 2026 | Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | -0.5% | +1.0% |
| Apr 23, 2026 | Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026 | -4.2% | -0.4% |
| Apr 10, 2026 | Viking Therapeutics to Participate at Upcoming Investor Conferences | -2.0% | -0.1% |
Keep researching VKTX
- VKTX insider tradesEvery buy and sale reported by Viking Therapeutics Inc. officers, directors and large holders.
- VKTX earnings historyPast Viking Therapeutics Inc. earnings releases, newest first.
- VKTX financial statementsRevenue, profit, cash flow and balance sheet from Viking Therapeutics Inc.'s SEC filings.
Quantisnow market dataNASDAQ
VKTX
Viking Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2015
Get push alerts for VKTX
Full VKTX profile on Quantisnow Follow VKTX and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time